Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step to translate anticancer immune responses into long-lasting clinical benefits.
Keywords: cancer immunotherapy; dendritic-cell targeting; dendritic-cell vaccination; myeloid dendritic cells; plasmacytoid dendritic cells.